Stay updated on SWIPE: Pembrolizumab Switch in NSCLC Clinical Trial
Sign up to get notified when there's something new on the SWIPE: Pembrolizumab Switch in NSCLC Clinical Trial page.

Latest updates to the SWIPE: Pembrolizumab Switch in NSCLC Clinical Trial page
- CheckyesterdayChange DetectedStrovolos is now listed as a study location under Locations, and the Strovolos Locations entry has been removed. The page revision is updated to v3.3.3.SummaryDifference0.2%

- Check15 days agoNo Change Detected
- Check29 days agoChange DetectedPublications are now described as auto-filled from PubMed and possibly not about the study. The page revision has been updated to v3.3.2.SummaryDifference0.1%

- Check36 days agoChange DetectedRemoved the operating status notice about government funding and NIH Clinical Center operations. The notice previously warned about potential delays and status updates unrelated to the study details.SummaryDifference0.4%

- Check51 days agoChange DetectedResults data for the SWIPE trial (NCT02705820) have been added, including primary and secondary outcomes and adverse events, with updated study record dates reflecting posted results.SummaryDifference0.5%

- Check79 days agoChange DetectedCore content updated to v3.2.0 with a government-operating-status notice and a removal of the previous v3.1.0 marker.SummaryDifference3%

- Check86 days agoChange Detected- Updated version from v3.0.2 to v3.1.0. - No other content changes detected.SummaryDifference0.1%

Stay in the know with updates to SWIPE: Pembrolizumab Switch in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the SWIPE: Pembrolizumab Switch in NSCLC Clinical Trial page.